Abstract:Four series of new 3-nitro naphthalimides derivatives, 4(4a‒4f), 5(5a‒5i), 6(6a‒6e) and 7(7a‒7j), were designed and synthesized as antitumor agents. Methyl thiazolyl tetrazolium (MTT) screening assay results revealed that some compounds displayed effective in vitro antiproliferative activity on SMMC-7721, T24, SKOV-3, A549 and MGC-803 cancer cell lines in comparison with 5-fluorouracil (5-FU), mitonafide and amonafide. Nude mouse xenotransplantation model assay results indicated that compounds 6b and 7b exhibited good in vivo antiproliferative activity in MGC-803 xenografts in comparison with amonafide and cisplatin, suggesting that compounds 6b and 7b could be good candidates for antitumor agents. Gel electrophoresis assay indicated that DNA and Topo I were the potential targets of compounds 6b and 7b, and comet assay confirmed that compounds 6b and 7b could induce DNA damage, while the further study showed that the 6b- and 7b-induced DNA damage was accompanied by the upregulation of p-ATM, P-Chk2, Cdc25A and p-H2AX. Cell cycle arrest studies demonstrated that compounds 6b and 7b arrested the cell cycle at the S phase, accompanied by the upregulation of the expression levels of the antioncogene p21 and the down-regulation of the expression levels of cyclin E. Apoptosis assays indicated that compounds 6b and 7b caused the apoptosis of tumor cells along with the upregulation of the expression of Bax, caspase-3, caspase-9 and PARP and the downregulation of Bcl-2. These mechanistic studies suggested that compounds 6b and 7b exerted their antitumor activity by targeting to DNA, thereby inducing DNA damage and Topo I inhibition, and consequently causing S stage arrest and the induction of apoptosis.

Design, Synthesis And Biological Evaluation Of Tasiamide Analogues As Tumor Inhibitors

Antitumor Agents 268. Design, Synthesis, and Mechanistic Studies of New 9-Substituted Phenanthrene-Based Tylophorine Analogues As Potent Cytotoxic Agents.

Design, synthesis and in vitro evaluation of tylophorine derivatives as possible anti-tumor agents.

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Design, synthesis, and bioactivities of tasiamide B derivatives as cathepsin D inhibitors.

Synthesis and biological evaluation of novel podophyllotoxin analogs as antitumor agents.

Design, Synthesis and Antitumor Evaluation of a New Series of N-substituted-thiourea Derivatives

Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations

Design, synthesis, and biological evaluation of simplified tetrahydroisoquinoline analogs

Design, Synthesis and Biological Evaluation of N-phenylsulfonylnicotinamide Derivatives As Novel Antitumor Inhibitors.

Design, Synthesis, and Biological Evaluation of a Class of TEMPOmodified Naphthalimide Derivatives with Good Selectivity for Tumor Cells

Synthesis and cytotoxic evaluation of novel symmetrical taspine derivatives as anticancer agents.

Design, Synthesis, Antitumor Activity Evaluation, and Molecular Dynamics Simulation of Some 2-Aminopyrazine Derivatives

Design, synthesis and cytotoxic evaluation of novel betulonic acid-diazine derivatives as potential antitumor agents

Structural Modification and Inhibitory Activity on Tumor Cell Proliferation of Novel Diaryl-β-lactam Compounds As Tubulin Aggregation Inhibitors

Design, synthesis and biological evaluation of tasiamide B derivatives as BACE1 inhibitors.

Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA

Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.

Design, synthesis and biological evaluation of 4-(4-aminophenoxy)picolinamide derivatives as potential antitumor agents

Design, Synthesis, Biological Evaluation, and Molecular Docking Studies of N3‐Functionalized TZD‐Indole Conjugates as Potential Anticancer Agents

Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors